The Evolution of the Pharmaceutical Industry Over the Past 50 Years: A Personal Reflection
Author
Abstract
Suggested Citation
DOI: 10.1080/13571516.2011.584421
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Ernst Berndt & Murray Aitken, 2011. "Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 18(2), pages 177-201.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Li, Lei & Li, Dan & Goerzen, Anthony & Shi, Weilei (Stone), 2018. "What and how do SMEs gain by going international? A longitudinal investigation of financial and intellectual resource growth," Journal of World Business, Elsevier, vol. 53(6), pages 817-834.
- Yong J. Yoon, 2017. "Buchanan on increasing returns and anticommons," Constitutional Political Economy, Springer, vol. 28(3), pages 270-285, September.
- Saswati Tripathi & Bijoy Talukder & Krishnamachari Rangarajan, 2024. "Do Supply Chain Performance Influence Firm Profitability? A Predictive Approach in the Context of the Indian Pharmaceutical Industry," IIM Kozhikode Society & Management Review, , vol. 13(2), pages 166-183, July.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022.
"Generic competition and the incentives for early-stage pharmaceutical innovation,"
Research Policy, Elsevier, vol. 51(10).
- Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2014. "Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation," NBER Working Papers 20532, National Bureau of Economic Research, Inc.
- Roger Feldman & Félix Lobo, 2013. "Competition in prescription drug markets: the roles of trademarks, advertising, and generic names," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(4), pages 667-675, August.
- Keith M. Drake & Martha A. Starr & Thomas McGuire, 2014. "Do "Reverse Payment" Settlements of Brand-Generic Patent Disputes in the Pharmaceutical Industry Constitute an Anticompetitive Pay for Delay?," NBER Working Papers 20292, National Bureau of Economic Research, Inc.
- Serra-Sastre, Victoria & Bianchi, Simona & Mestre-Ferrandiz, Jorge & O’Neill, Phill, 2021. "Does NICE influence the adoption and uptake of generics in the UK?," LSE Research Online Documents on Economics 113639, London School of Economics and Political Science, LSE Library.
- Christopher Ody & Matt Schmitt, 2019. "Who cares about a label? The effect of pediatric labeling changes on prescription drug utilization," International Journal of Health Economics and Management, Springer, vol. 19(3), pages 419-447, December.
- Berndt, Ernst R. & Dubois, Pierre, 2012.
"Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010,"
IDEI Working Papers
702, Institut d'Économie Industrielle (IDEI), Toulouse.
- Berndt, Ernst R. & Dubois, Pierre, 2012. "Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010," TSE Working Papers 12-283, Toulouse School of Economics (TSE).
- Berndt, Ernst R & Dubois, Pierre, 2012. "Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010," CEPR Discussion Papers 9140, C.E.P.R. Discussion Papers.
- Leemore Dafny & Christopher Ody & Matt Schmitt, 2017.
"When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization,"
American Economic Journal: Economic Policy, American Economic Association, vol. 9(2), pages 91-123, May.
- Leemore Dafny & Christopher Ody & Matthew Schmitt, 2016. "When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization," NBER Working Papers 22745, National Bureau of Economic Research, Inc.
- Sotiris Vandoros, 2014. "Therapeutic Substitution Post‐Patent Expiry: The Cases Of Ace Inhibitors And Proton Pump Inhibitors," Health Economics, John Wiley & Sons, Ltd., vol. 23(5), pages 621-630, May.
- Mats A. Bergman & David Granlund & Niklas Rudholm, 2017. "Squeezing the Last Drop Out of Your Suppliers: An Empirical Study of Market-Based Purchasing Policies for Generic Pharmaceuticals," Oxford Bulletin of Economics and Statistics, Department of Economics, University of Oxford, vol. 79(6), pages 969-996, December.
- Rena M. Conti & Ernst R. Berndt, 2019. "Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets," NBER Working Papers 26194, National Bureau of Economic Research, Inc.
- Pierre Dubois; & Laura Lasio;, 2012. "The effects of price regulation of pharmaceutical industry margins: A structural estimation for anti-ulcer drugs in France," Health, Econometrics and Data Group (HEDG) Working Papers 12/18, HEDG, c/o Department of Economics, University of York.
- Arcidiacono, Peter & Ellickson, Paul B. & Landry, Peter & Ridley, David B., 2013.
"Pharmaceutical followers,"
International Journal of Industrial Organization, Elsevier, vol. 31(5), pages 538-553.
- Peter Arcidiacono & Paul B. Ellickson & Peter Landry & David B. Ridley, 2013. "Pharmaceutical Followers," NBER Working Papers 19522, National Bureau of Economic Research, Inc.
- Barry Bosworth & John Bieler & Michael Kleinrock & Eric Koepcke & Ernst R. Berndt, 2018. "An Evaluation of the CPI Indexes for Prescription Drugs," NBER Working Papers 24210, National Bureau of Economic Research, Inc.
- González, Paula & Macho-Stadler, Inés & Pérez-Castrillo, David, 2016.
"Private versus social incentives for pharmaceutical innovation,"
Journal of Health Economics, Elsevier, vol. 50(C), pages 286-297.
- Paula González & Ines Macho-Stadler & David Pérez-Castrillo, 2015. "Private versus Social Incentives for Pharmaceutical Innovation," CESifo Working Paper Series 5672, CESifo.
- Inés Macho-Stadler & David Pérez-Castrillo & Paula González, 2015. "Private versus Social Incentives for Pharmaceutical Innovation," Working Papers 860, Barcelona School of Economics.
- Paula González & Inés Macho-Stadler & David Pérez-Castrillo, 2015. "Private versus Social Incentives for Pharmaceutical Innovation," Working Papers 15.07, Universidad Pablo de Olavide, Department of Economics.
- Victoria Serra-Sastre & Simona Bianchi & Jorge Mestre-Ferrandiz & Phill O’Neill, 2021. "Does NICE influence the adoption and uptake of generics in the UK?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(2), pages 229-242, March.
- Neha Bairoliya & Pinar Karaca-Mandic & Jeffrey S. McCullough & Amil Petrin, 2017. "Consumer Learning and the Entry of Generic Pharmaceuticals," NBER Working Papers 23662, National Bureau of Economic Research, Inc.
- Keisuke Hattori & Keisaku Higashida, 2023. "Who should be regulated: Genuine producers or third parties?," Journal of Economics, Springer, vol. 138(3), pages 249-286, April.
- Lamar Hunt & Irene B. Murimi & Jodi B. Segal & Marissa J. Seamans & Daniel O. Scharfstein & and Ravi Varadhan, 2020. "Brand versus generic: addressing non‐adherence, secular trends and non‐overlap," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 183(4), pages 1461-1478, October.
- Ernst R. Berndt & Rena M. Conti & Stephen J. Murphy, 2017. "The Landscape of US Generic Prescription Drug Markets, 2004-2016," NBER Working Papers 23640, National Bureau of Economic Research, Inc.
- Farasat A. S. Bokhari & Franco Mariuzzo & Arnold Polanski, 2020.
"Entry limiting agreements: First‐mover advantage, authorized generics, and pay‐for‐delay deals,"
Journal of Economics & Management Strategy, Wiley Blackwell, vol. 29(3), pages 516-542, July.
- Farasat A.S. Bokhari & Franco Mariuzzo & Arnold Polanski, 2020. "Entry limiting agreements: First mover advantage, authorized generics and pay-for-delay deals," Working Paper series, University of East Anglia, Centre for Competition Policy (CCP) 2015-05v4, Centre for Competition Policy, University of East Anglia, Norwich, UK..
More about this item
Keywords
Pharmaceuticals; Innovation; R&D; Biotechnology; Generics; Alliances;All these keywords.
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:taf:ijecbs:v:18:y:2011:i:2:p:161-176. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Chris Longhurst (email available below). General contact details of provider: http://www.tandfonline.com/CIJB20 .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.